Semaglutide, a glucagon like peptide-one (GLP-1) receptor agonist, is accessible as monotherapy in both equally subcutaneous and oral dosage form (first accepted oral GLP-1 receptor agonist). It's been authorized as being a next line treatment selection for greater glycaemic Handle in variety two diabetes and at present beneath scrutiny for https://anthonya322mxi4.empirewiki.com/user